AAN Issues Review of Evidence for Aducanumab in Alzheimer Disease
Class I study shows single doses of aducanumab safe, well tolerated; class II studies show reduced amyloid deposition on brain PET at one year
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.